Results 41 to 50 of about 69,008 (285)

EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer

Advanced Science, EarlyView.
This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv, Zihang Lin, Jiandong Sun, Yuhong Ye, Qibin Wu, Liangzhi Cai, Dabin Liu, Pengming Sun, Shie Wang   +8 more
wiley   +1 more source

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis

BMC Cancer
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Molecular Cancer, 2022
Background Approximate 25% HER2-positive (HER2+) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.
Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong   +17 more
doaj   +1 more source

Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles

Advanced Science, EarlyView.
The proximity labeling enzyme APEX2 is displayed on extracellular vesicle (EV) surfaces via genetic fusion with EV‐sorting scaffolds, enabling in situ biotinylation of native surface proteins, adsorbed corona components, and interacting cellular proteins.
Wenyi Zheng, Metoboroghene Mowoe, Wenqing Hou, Daniel W. Hagey, Koshi Imami, Samir EL Andaloussi   +5 more
wiley   +1 more source

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Health Technology Assessment, 2020
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn   +26 more
doaj   +1 more source

Bacteriophage‐Mimetic DNA Origami Needle for Targeted Membrane Penetration and Cytosolic Cargo Delivery

Advanced Science, EarlyView.
We designed a synthetic DNA origami needle‐like structure inspired by bacteriophages for targeted drug delivery. Functionalized with trastuzumab antibodies, cholesterol, and dyes, it selectively targets SKBR3 cancer cells. A glutathione‐triggered dye payload enables controlled release, and delivery is verified using confocal microscopy and live cell ...
Anirban Samanta, Mette Galsgaard Malle, Emily Tsang, Marjan Omer, Mads K. Skaanning, Sarah Youssef, Jørgen Kjems, Kurt V. Gothelf   +7 more
wiley   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source

A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway

Journal of Hematology & Oncology, 2016
Background Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive gastric cancer. However, recurrent therapeutic resistance presents revolutionary claims.
Jing Liu, Changqie Pan, Lihong Guo, Mengwan Wu, Jing Guo, Sheng Peng, Qianying Wu, Qiang Zuo   +7 more
doaj   +1 more source

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. [PDF]

PLoS ONE, 2012
OBJECTIVE: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial
Takehiro Ichikawa, Fumiaki Sato, Kazuya Terasawa, Soken Tsuchiya, Masakazu Toi, Gozoh Tsujimoto, Kazuharu Shimizu   +6 more
doaj   +1 more source